# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar

> **NCT05762393** · PHASE1 · COMPLETED · sponsor: **International Vaccine Institute** · enrollment: 120 (actual)

## Conditions studied

- Schistosomiasis

## Interventions

- **BIOLOGICAL:** rSm-p80 + GLA-SE

## Key facts

- **NCT ID:** NCT05762393
- **Lead sponsor:** International Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-17
- **Primary completion:** 2025-05-19
- **Final completion:** 2025-05-19
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05762393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05762393, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05762393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*